Project Grant R01AG094161
Award Date
5/15/25
Completion Date
1/31/30
Dollars Obligated
$782K
Federal Agency
National Institute on Aging
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to image the GPR39 receptor in Alzheimer's disease (AD). The project aims to: 1) investigate the imaging utility of [11C]TM-N1324 in rodent models overexpressing or lacking GPR39, as well as in an AD transgenic mouse model, correlating PET outcomes...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $2,969,644 to develop a novel positron emission tomography (PET) imaging probe targeting myeloperoxidase (MPO) activity for detecting neuroinflammation in neurodegenerative diseases. The Massachusetts General Hospital will design and screen potential PET agents for detecting MPO activity in the brain, characterize and validate candidate MPO PET...
This federal Project Grant award of $528,876.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University will support a 5-year research study to investigate the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias (AD/ADRD). The key objectives are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) for transcriptome-wide genes and proteome-wide proteins across multiple brain...
This $837,500 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports research to characterize the properties and performance of the PET radiotracer [18F]3F4AP for detecting and quantifying demyelination and cerebral perfusion in Alzheimer's disease, mild cognitive impairment, and cognitively normal individuals. The project aims to conduct the first full pharmacokinetic evaluation of [18F]3F4AP in human subjects and validate...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $805,738 in funding to the Battelle Memorial Institute's Pacific Northwest National Laboratory Division, operating as Pacific NW National, to conduct research on the role of brain lipoproteins in the development of Alzheimer's disease. The key objectives of this 5-year project are to: 1) assess the impact of different apolipoprotein E (ApoE) isoforms on the distribution, composition, and...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $233,402 project grant to the University of Missouri System to develop novel fluorine-18 (F-18) positron emission tomography (PET) radiotracers targeting the alpha-2C adrenergic receptor (2C-AR) subtype. The project aims to evaluate these 2C-AR radiotracers and compare their properties to the existing carbon-11 labeled radiotracer [11C]ORM13070. Successful development of an improved...
This $504,732 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The awardee, Aphios Corp, will (1) nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, and (2) evaluate the impact of the nanoparticles on in vitro models of brain inflammation and blood-brain barrier penetration. The project aims to identify optimal nanoparticle candidates...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $812,030 to The Trustees of the University of Pennsylvania to develop and optimize noninvasive imaging biomarkers to track neuroinflammation in the early stages of Alzheimer's disease (AD). The research aims to explore the connections between neuroinflammation, brain glucose hypometabolism, and AD progression using advanced magnetic resonance imaging techniques like...
This Project Grant award, provided by the National Institute on Aging under CFDA Program 93.866 - Aging Research, aims to establish targeting the protein CAPON as a promising therapeutic strategy for Alzheimer's disease (AD). The $1,980,378 grant supports research to screen a chemical library for small molecule inhibitors of the CAPON-tau and CAPON-nNOS interactions, which are implicated in AD pathogenesis. The 3-year project will validate the therapeutic potential of optimized lead compounds...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $137,895 to The Regents of the University of California, Berkeley to investigate the network drivers of regional vulnerability to early Alzheimer's disease pathology. The project will use positron emission tomography (PET) imaging and resting-state functional MRI to examine how functional brain network connectivity is associated with Alzheimer's disease risk, longitudinal pathology...